Abstract
The major modalities of modem cancer therapy are surgery, radiotherapy, chemotherapy, and hormonal therapy. A role in the cancer treatment armamentarium is being established for immunotherapy and biological therapy. Biological therapy of cancer can be defined as the modification and exploitation of the cellular and molecular mechanisms of host defense and of the regulation of tissue proliferation, tissue differentiation, and tissue survival for use in the treatment of cancer. Cancer immunotherapy was first conceived in 1900 by Paul Erlich (1906), who postulated that antibodies could be used for targeting drugs and toxins to tumor cells. As we shall discuss, the production of highly specific monoclonal antibodies (MoAbs) using the hybridoma methodology of Kohier and Milstein (1975) has led to a present-day reappraisal of Erlich’s hypothesis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abdi, E. A., Kamitomo, V. J., McPherson, T. A., Konrad, M. W., Inque, M., and Tan, Y. H., 1986, Extended phase I study of human ß-interferon in human cancer, Clin. Invest. Med. 9:33–40.
Abdulhay, G., DiSaia, P. J., Blessing, J. A., and Creasman, W. T., 1985, Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: A Gynecologic Oncology Group study. Am. J. Obstet. Gynecol. 152:418–423.
Abrams, D. I., and Volberding, P. A., 1986, Alpha interferon therapy of AIDS-associated Kaposi’s sarcoma, Semin. Oncol. 13 (Suppl. 2):43–47.
Ainslie, J., Burdon, J. G. W., Henderson, M. M., Ilbery, P. L. T., and Matthews, J. P., 1983, The use of levamisole as an adjunct to chemotherapy and radiotherapy in the treatment of small cell carcinoma of the lung, Med. J. Aust. 2:285–287.
Aisner, J., Weinberg, V., Perloff, M., Weiss, R., Perry, M., Korzun, A., Ginsberg, S., and Holland, J. F., 1987, Chemotherapy versus chemoimmunotherapy (CAP v CAFVP v CMF each ± MER) for metastatic carcinoma of the breast: A CALGB study, J. Clin. Oncol. 5:1523–1533.
Alberts, D. S., Moon, T. E., Stephens, R. A., Wilson, H., Oishi, N., Hilgers, R. D., O’Toole, R., and Thigpen, J. T., 1979, Randomized study of chemoinmiunotherapy for advanced ovarian carcinoma: A preliminary report of a Southwest Oncology Group study. Cancer Treat. Rep. 63: 325–331.
Alberts, D., Mason, N., O’Toole, R., Kronmal, R., Hilgers, R., Surwit, E., Eyre, H., Baker, L., Boutsellis, J., Rivkin, S., Green, B., and Hannigan, E., 1986, Randomized phase III trial of doxorubicin (D) + cyclophosphamide (C) + BCG vs DC -H displatinum (P) vs DC -I- P -H BCG in stages III and IV ovarian cancer, Proc. ASCO 5:119.
Andriole, G. L., Mule, J. J., Hansen, C. T., Linehan, W. M., and Rosenberg, S. A., 1985, Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice, J. Immunol. 135:2911–2913.
Armitage, N. C., Perkins, A. C., Pimm, M. V., Wastie, M. L., Baldwin, R. W., and Hardcastle, J. D., 1985, Imaging of primary and metastatic colorectal cancer using an 111In-labelled antitumor monoclonal antibody (791T/36), Nucl. Med. Commun. 6:623–631.
Ashford, R., Priestman, T., Mott, T., and Bottomley, J. M., 1986, Combining interferon with cytotoxic chemotherapy in patients with advanced breast cancer. Cancer Immunol. Immunother. 23:217–219.
Astler, V. B., and Coller, F. A., 1954, The prognostic significance of direct extension of carcinoma of the colon and rectum, Ann. Surg. 139:846–852.
Azizi, E., Brenner, H. J., and Shoham, J., 1984, Postsurgical adjuvant treatment of malgnant melanoma patients by the thymic factor thymostimulin. Drug Res. 34:1043–1046.
Bach, J. F., Dardenne, M., Pleau, J. M., and Bach, M. A., 1975. Isolation, biochemical characteristics and biological activity of a circulating thymic hormone in the mouse and in the human, Ann. N.Y. Acad. Sci. 249:186–210.
Badalament, R. A., Herr, H. W., Wong, G. Y., Gnecco, C., Pinsky, C. M., Whitmore, W. F., Jr., Fair, W. R., and Oettgen, H. F., 1987, A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer, J. Clin. Oncol. 5:441–449.
Balch, C. M., and Milton, G. W., 1985, Diagnosis of metastatic melanoma at distant sites, in: Cutaneous Melanoma (C. M. Balch and G. W. Milton, eds.), J. B. Lippincott, Philadelphia, pp. 221–250.
Baldwin, R. W., and Byers, V. S., 1987, Monoclonal antibody targeting of cytotoxic agents for cancer therapy, in: Immunology of Malignant Diseases (V. S. Byers and R. W. Baldwin, eds.), MTP Press, Lancaster, pp. 44–54.
Baldwin, R. W., and Pimm, R. V., 1973, BCG immunotherapy of rat tumors of defined immu- nogenicity, Natl. Cancer Inst. Monogr. 39:11–17.
Baldwin, R. W., and Pimm, M. V., 1978, BCG in tumor immunotherapy. Adv. Cancer Res. 28:91–147.
Bast, R. C., 1982, Effects of cancers and their treatment on host immunity, in: Cancer Medicine (J. Holland and E. Frei, eds.), Ua & Febiger, Philadelphia, pp. 1134–1173.
Bast, R. C., Jr., and Knapp, R. C., 1984, Immunologic approaches to the management of ovarian carcinoma, Semin. Oncol. 11:264–274.
Bast, R. C., Zbar, B., Borsos, T., and Rapp, H. J., 1974, BCG and cancer, N. Engl. J. Med. 290: 1413–1420, 1458–1469.
Bast, R. C., Jr., Berek, J. S., Obrist, R., Griffiths, C. T., Berkowitz, R. S., Hacker, N. F., Parker, L., Lagasse, L. D., and Knapp, R. C., 1983, Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum, Cancer Res. 43:1395–1401.
Bedikian, A. Y., Patt, Y. Z., Murphy, W. K., Umsawasadi, T., Carr, D. T., Hersh, E. M., Bodey, P., and Valdivieso, M., 1984, Prospective evaluation of thymosin fraction V immunotherapy in patients with non-small cell lung cancer receiving vindesine, doxorubicin, and cisplatin (VAP) chemotherapy. Am. J. Clin. Oncol. 7:399–404.
Bensinger, W. I., Buckner, C. D., Clift, R. A., and Thomas, E. D., 1984, Clinical trials with staphylococcal protein A, J. Biol. Respir. Mod. 3:347–351.
Berd, V., Maguire, H. C., Jr., and Mastrangelo, M. J., 1984a, Impairment of concanavalin A inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer. Cancer Res. 44:1275–1280.
Berd, V., Maguire, H. C., Jr., and Mastrangelo, M. J., 1984b, Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphomide. Cancer Res. 44:5439–5443.
Berd, D., Maguire, H. C., Jr., and Mastrangelo, M. J., 1986, Induction of cell-mediated inmiunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide, Cancer Res. 46:2572–2577.
Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., Know, R. M., Brady, J., Greene, T., Ettmger, L. M., Lagasse, L. D., Bonnem, E. M., Spiegel, R. J., and Zighelboim, J., 1985a, Intraperitoneal recombinant a-interferon for “salvage” immunotherapy in stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Cancer Res. 45: 4447–4453.
Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., Knox, R. M., Brady, J., Greene, T., Ettinger, L. M., Lagasse, L. D., Bonnem, E. M., Spiegel, R. J., and Zighelboim, J., 1985b, Intraperitoneal recombinant a2-interferon for “salvage” immunotherapy in persistent epithelial ovarian cancer. Cancer Treat. Rev. 12:23–32.
Berek, J. S., Knapp, R. C., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., Obrist, R., Griffiths, C. T., Berkowitz, R. S., Parker, L., Zighelboim, J., and Bast, R. C. Jr., 1985c, Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. Am. J. Obstet. Gynecol. 152:1003–1010.
Bogdahn, U., Fleischer, B., Hilfenhaus, J., Rothig, H. J., Krauseneck, P., Mertens, H. G., Przuntek, H., 1985, Interferon-ß in patients with low-grade astrocytomas—A phase I study, J. Neurooncol. 3:125–130.
Bonadonna, G., Valagussa, P., Tancini, G., Rossi, A., Brambilla, C., Zambetti, M., Bignami, P., Di Fronzo, G., and Silvestrini, R., 1986, Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer, Natl. Cancer Inst. Monogr. 1:45–49.
Branca, A. A., and Baglioni, C., 1981, Evidence that types I and II interferons have different receptors. Nature 294:768–770.
Brandt, S. J., Peters, W. P., Atwater, S. K., Kurtzberg, J., Borowitz, M. J., Jones, R. B., Shpall, E. J., Bast, R. C., Jr., Gilbert, C. J., and Oette, D. H., 1988, Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high- dose chemotherapy and autologous bone marrow transplantation, N. Engl. J. Med. 318:869–876.
Graun, D. P., Nisius, S., Hollinshead, A., and Harris, J. E., 1983, Serial inmiune testing in surgically resected lung cancer patients. Cancer Immunol. Immunother. 15:114–120.
Brosman, S.A., 1982, Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma, J. Urol. 128:27–29.
Brown, T. D., Koeller, J., Beougher, K., Galando, J., Bonnem, E. M., Spiegel, R. J., and Von Hoff, D. D., 1987, A phase I cünical trial of recombinant DNA gamma interferon, J. Clin. Oncol 5:790–798.
Brunda, M. J., Bellatoni, D., and Sulich, V., 1987, In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int. J. Cancer 40:365–371.
Bubenik, J., Peremann, P., Helmstain, and Moberger, G., 1970, Cellular and humoral immune responses to human urinary bladder carcinomas. Int. J. Cancer 5:310–319.
Bullard, D. E., and Bigner, D. D., 1985, Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors, J. Neurosurg. 63:2–16.
Bullard, D. E., Gillespie, G. Y., Mahaley, M. S., and Bigner, D. D., 1986, Immunobiology of human gliomas, Semin. Oncol. 13:94–109.
Buraggi, G. L., Callegaro, L., Turrin, A., Cascinelli, N., Attili, A., Emanuelli, H., Gasparini, M., Deleide, G., Plassio, G., and Dovis, M., 1984, Immunoscintigraphy with 123I 99mTc(prime) 111 In-labelled F(ab1)2 fragments of monoclonal antibodies to a human high molecular weight melanoma associated antigen, J. Nucl. Med. Allied Sci. 28:283–295.
Buzaid, A. C., Robertone, A., Kisala, C., and Salmon, S. E., 1987, Phase II study of interferon alpha-2a, recombinant (roferon-A) in metastatic renal cell carcinoma, J. Clin. Oncol. 5:1083–1089.
Bystryn, J.-C., 1985, Immunology and immunotherapy of human malignant melanoma, Dermatol. Clin. 3:327–334.
Cancer Patient Survival Report Number 5, 1911, DHEW Publ. No. (NIH) 77–992, DHEW, Washington.
Carpenter, J. T., Jr., Smalley, R. V., Raney, M., Vogel, C. L., and Weiner, R. S., 1986, Ineffectiveness of levamisole in prolonging remission or survival or women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: A Southeastern Cancer Study Group trial. Cancer Treat. Rep. 70:1073–1079.
Carrel, S., de Tribolet, N., and Gross, N., 1982, Expression of HLA-DR and common acute lymphoblastic leukemia antigens on glioma cells, Eur. J. Immunol. 12:354–357.
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B., 1975, An endotoxin induced serum factor that causes necrosis of tumors, Proc. Natl. Acad. Sci. U.S.A. 72:3666–3670.
Catalona, W. J., Hudson, M. A., Gillen, D. P., Andriole, G. L., and Ratliff, T. L., 1987, Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer, J. Urol. 137:220–224.
Ceriani, R. L., Peterson, J. A., and Blank, E. W., 1987, Experimental immunotherapy of breast cancer with anti-breast epithelial monoclonal antibody radioconjugates, Proc. AACR 28:394.
Cheung, N.-K. V., Lazarus, H., Miraldi, F. D., Abramowsky, C. R., Kallick, S., Saarinen, U. M., Spitzer, T., Strandjord, S. E., Coccia, P. F., and Berger, N. A., 1987, Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma, J. Clin. Oncol. 5:1430–1440.
Choo, Y. C., Hsu, C., Seto, W. H., Miller, D. G., Merigan, T. C., Ng, M. H., and Ma, H. K., 1985, Intravaginal application of leukocyte interferon gel in the treatment of cervical intraepithelial neolasia (CIN), Arch. Gynecol. 237:51–54.
Choo, Y. C., Seto, W. H., Hsu, C., Merigan, T. C., Tan, Y. H., Ma, H. K., and Ng, M. H., 1986, Cervical intraepithelial neoplsia by perilesional injection of interferon, Br. J. Obstet. Gynaecol. 93:372–379.
Clark, S. C., and Kamen, R., 1987, The human hematopoietic colony-stimulating factors. Science 236:1229–1237.
Clark, W. H., Ainsworth, A. M., Bernardino, E. A., Yang, C. H., Mihm, M. C., and Reed, R. J., 1975, The developmental biology of primary human malignant melanomas, Semin. Oncol. 2: 83–103.
Clemens, M., 1985, Interferons and oncogenes. Nature 313:531–532.
Coakham, H., 1974, Surface antigen(s) common to human astrocytoma cells. Nature 250:328–330.
Coakham, H. B., and Lakshmi, M. S., 1975, Tumor-associated surface antigen(s) in human astrocytomas, Oncology 31:233–243.
Coates, A., Railings, M., Hersey, R., and Swanson, C., 1986, Phase-II study of recombinant a2- interferon in advanced malignant melanoma, J. Interferon Res. 6:1–4.
Cohen, M. H., Chretien, P. B., Ihde, D. C., Fossieck, B. E., Makuch, R., Bunn, P. A., Jr., Johnston, A. V., Shackney, S. E., Matthews, M. J., Lipson, S. D., Kenady, D. E., and Minna, J. D., 1979, Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small cell lung cancer, J.A.M.A. 241:1813–1815.
Colcher, D., Esteban, J. M., Carrasquillo, J. A., Sugarbaker, P., Reynolds, J. C., Bryant, G., Larson, S. M., and Schlom, J., 1987, Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Res. 411 1185–1189.
Connors, J. M., Andiman, W. A., Howarth, C. B., Liu, E., Merigan, T. C., Savage, M. E., and Jacobs, C., 1985, Treatment of nasopharyngeal carcinoma with human leukocyte interferon, J. Clin. Oncol. 3:813–817.
Creagan, E. T., Ahmann, D. L., Green, S. J., Long, H. J., Rubin, J., Schutt, A. J., and Dziewanowski, Z. E., 1984a, Phase II study of recombinant leukocyte A interferon (rIFN-aA) in disseminated malignant melanoma. Cancer 54:2844–2849.
Creagan, E. T., Ahmann, D. L., Green, S. J., Long, H. J., Frytak, S., O’Fallon, J. R., and Itri, L. M., 1984b, Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma, J. Clin. Oncol. 2:1002–1005.
Creagan, E. T., Ahmann, D. L., Green, S. J., Long, H. J., Frytak, S., and Itri, L. M., 1985, Phase II study of recombinant leukocyte A interferon (IFN-rA) plus Cimetidine in disseminated malignant melanoma, J. Clin. Oncol. 3:977–981.
Creasman, W. T., and Clarke-Pearson, D. L., 1983, Immunotherapy of ovarian cancer, Clin. Obstet. Gynaecol. 10:297–306.
Creasman, W. T., Gall, S. A., Blessing, J. A., Schmidt, H. J., Abu-Ghazaleh, S., Whisnant, J. K., and DiSaia, P. J., 1979, Chemoimmunotherapy in the management of primary stage III ovarian cancer: A Gynecologic Oncology Group study, Cancer Treat. Rep. 63:319–323.
DeKemion, J. B., Huang, M.-Y, Lindner, A., Smith, R. B., and Kaufman, J. J., 1985, The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin, J. Urol. 133:598–601.
Dellon, A. C., Potvin, C., and Chretien, P. B., 1975, Thymus-dependent lymphocyte levels in bronchogenic carcinoma; correlations with histology, clinical stage and clnical coarse after surgical treatment. Cancer 35:687.
Dinarello, C. A., and Mier, J. W., 1987, Lymphokines: Current concepts, N. Engl. J. Med. 317: 940–945.
Dippold, W. G., Knuth, A., and Meyer zum Buschenfelde, K.-H., 1984, Inhibition of human melanoma cell growth in vitro by monoclonal anti-Goa-ganglioside antibody. Cancer Res. 44: 806–810.
DiSaia, P. J. Bundy, B. N., Curry, S. L., Schlaerth, J., and Thigpen, J. T., 1987, Phase III study on the treatment of women with cervical cancer, stage IIB, HIB, and IVA (confined to the pelvis and/or periaortic nodes), with radiotherapy alone versus radiotherapy plus immunotherapy with intravenous Corynebacterium parvum: A Gynecologic Oncology Group study, Gynecol. Oncol. 26:386–397.
Dolei, A., Capobianchi, M. R., and Ameglio, F., 1983, Human interferon-7 enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than interferon-a and interferon-ß. Infect. Immun. 40:172–176.
Donaldson, R. C., 1972, Methotrexate plus Bacillus Calmette-Guerin (BCG) and isoniazid in the treatment of cancer of the head and neck. Am. J. Surg. 124:527–534.
Douillard, J.-Y., Le Mevel, B., Curtet, C., Vignoud, J., Chatal, J. F., and Koprowski, H., 1986, Immunotherapy of gastrointestinal cancer with monoclonal antibodies, Med. Oncol. Tumor Pharmacother. 3:141–146.
Droller, M. J., 1987, Biologic response modifiers in genitourinary neoplasia. Cancer 60:635–644.
Duff, T. A., Borden, E., Bay, J., Piepmeier, J., and Sielaff, K., 1986, Phase II trial of interferon-ß for treatment of recurrent glioblastoma multiforme, J. Neurosurg. 64:408–413.
Eggermont, A. M., Weimar, W., Marquet, R. L., Lameris, J. D., and Jeekel, J., 1985, Phase II trial of high-dose recombinant leukocyte alpha-2 interferon for metastatic colorectal cancer without previous systemic treatment. Cancer Treat. Rep. 69:185–187.
Eggermont, A. M., Weimar, W., and Tank, B., 1986, Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-aA (rIFNaA), Cancer Immunol. Imunother. 21:81–84.
Eisenthal, A., Lafreniere, R., Lefor, A. T., and Rosenberg, S. A., 1987, Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res. 47:2771–2776.
Epenetos, A. A., Munro, A. J., Stewart, S., Rampling, R., Lambert, H. E., McKenzie, C. G., Soutter, P., Rahemtulla, A., Hooker, G., Sivolapenko, G. B., Snook, D., Courtenay-Luck, N., Ghokia, B., Krausz, T., Taylor-Papadimitriou, J., Durbin, H., and Bodmer, W. F., 1987, Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies, J. Clin. Oncol. 5:1890–1899.
Eriksson, B., Oberg, K., Aim, G., Karlsson, A., Lundqvist, G. Magnusson, A., Wide, L., and Wilander, E., 1987, Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. Cancer Treat. Rep. 71:31–37.
Eriich, P., 1906 Chemotherapy, in: The Collection of Papers by Paul Erlich (F. Himmelweit, ed.), Pergamon Press, London.
Eschbach, J. W., Egrie, J. C., Downing, M. R., Browne, J. K., and Adamson, J. W., 1987, Correction of the anemia of end stage renal disease with recombinant human erythropoietin, N. Engl. J. Med. 316:73–78.
Estabrook, A., Yemul, S., Seldin, D., Link, M. J., and Kramer, P., 1987, Immunoimaging and biodistribution studies with 111I-Indium labeled monoclonal antibody to breast cancer, Proc. AACR 28:356(1410).
Everson, T. C., and Cole, W. H., 1966, Spontaneous regression of adenocarcinoma of the kidney (hypernephroma), in: Spontaneous Regression of Cancer, W. B. Saunders, Philadelphia, pp. 11–87.
Fauci, A. S., Macher, A. M., Longo, D. L., Lane, H. C., Rook, A. H., Masur, H., and Gelmann, E. P., 1984, Acquired immune deficiency syndrome: Epidemiologic, clinical, immunologic and therapeutic considerations, Ann. Intern. Med. 100:92–106.
Figlin, R. A., deKemion, J. B., Maldazys, J., and Sarna, G., 1985, Treatment of renal cell carcinoma with a(human leukocyte) interferon and vinblastine in combination: A phase I-II trial, Cancer Treat. Rep. 69:263–267.
Finger, H., Emmerling, P., and Bruss, E., 1970, Variable adjuvant activity of Bordetella pertussis with respect to the primary and secondary immunization of mice.Infect. Immun. 1:251.
Fischer, S. P. Lindermuth, J., Hash, C., and Shenkin, H. A., 1985, Levamisole in the treatment of glioblastoma multiforme, J. Surg. Oncol. 28:214–216.
Fischl, M., Lucas, S., Richman, S., and Koch, G., 1987, Phase II study of wellferon (WFN) and vincristine (VCR) in AIDS-related Kaposi’s sarcoma (KS), Proc. ASCO 6:2.
Fisher, B., Redmon, C., Fisher, E. R., and Wolmark, N., 1986, Systemic adjuvant therapy in treatment of primary operable breast cancer: National surgical adjuvant breast and bowel project experience, Natl. Cancer Inst. Monogr. 1:35–43.
Fisher, R. I., Coltmlan, C. A., Doroshow, J. H., Rayner, A. A., Hawkins, M. J., Mier, J. W., Wiemik, P., McMannis, J. D., Weiss, G. R., Margolin, K. A., Gemlo, B. T., Hoth, D. F., Parkinson, D. R., and Paietta, E., 1988, Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells, Ann. Intem. Med. 108:518–523.
Foon, K. A., Sherwin, S. A., Abrams, P. G., Stevenson, H. C., Holmes, P., Maluish, A. E., Oldham, R. K., and Herberman, R. B., 1985, A phase I trial of recombinant gamma interferon in patients with cancer. Cancer Immunol. Immunother. 20:193–197.
Fossa, S. D., and de Garis, S. T., 1987, Further experience with recombinant interferon alpha-2a with vinblastine in metastatic renal cell carcinoma: A progress report, Int. J. Cancer (Suppl. 1): 36–40.
Fowler, J. E., Jr., 1986, Failure of immunotherapy for metastatic renal cell carcinoma, J. Urol. 135: 22–25.
Frankel, A. E., Houston, L. L., and Issell, B. F., 1986, Prospects for immunotoxin therapy in cancer, Annu. Rev. Med. 37:125–142.
Friedman-Kien, A. E., Laubenstein, L. J., Rubinstein, P., Buimovici-Klein, E., Marmor, M., Stahl, R., Spigland, I., Kim, K. S., and Zolla-Pazner, S., 1982, Disseminated Kaposi’s sarcoma in homosexual men, Ann. Intern. Med. 96:693.
Fritze, D., Massner, B., Becher, R., Kaufmann, M., Illiger, H. J., Hartlapp, J., Queiber, W., Abel, U., Edler, L., Mayr, A. C., Drings, P., Westerhausen, M., Jungi, W., and Senn, H. J., 1984, Combination chemotherapy (VAC/FMC) with immunostimulation in metastatic breast cancer: A randomized study comparing different times and routes of administration of Corynebacterium parvum, Klin. Wochenschr. 62:162–167.
Fujimoto, S., Green, M. L, and Sehon, A. H., 1976, Regulation of the immune response to tumor antigens. L Immunosuppressor cells in tumor bearing hosts, J. Immunol. 116:791–799.
Fujisawa, T., Yamaguchi, Y., Kimura, H., Arita, M., Baba, M., and Shiba, M., 1984, Adjuvant immunotherapy of primary resected lung cancer with transfer factor, Cancer 54:663–669.
Fujita, K., 1987, The role of adjunctive immunotherapy in superficial bladder cancer. Cancer 59: 2027–2030.
Garfield, D. H., and Kennedy, B. J., 1972, Regression of metastatic renal cell carcinoma following nephrectomy. Cancer 30:190–196.
Garnett, M. C., and Baldwin, R. W., 1986, An improved synthesis of a methotrexate-albumin- 791T/36 monoclonal antibody conjugate cytotoxic to osteogenic sarcoma cell lines. Cancer Res. 46:2407–2412.
Gastrointestinal Tumor Study Group, 1984, Adjuvant therapy of colon cancer: Results of a prospectively randomized trial, N. Engl. J. Med. 310:737–743.
Gelmann, E. P., Preble, O. T., Steis, R., Lane, H. C., Rook, A. H., Wesley, M., Jacob, J., Fauci, A., Masur, H., and Longo, D., 1985, Human lymphoblastoid interferon treatment of Kaposi’s sarcoma in the acquired immune deficiency syndrome. Am. J. Med. 78:737–743
Giacomini, P., Aguzzi, A., Pestka, S., Fisher, P. B., and Ferrone, S., 1984, Modulation by recombinant DNA leukocyte (α) and fibroblast (β) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells, J. Immunol. 133:1649–1655.
Gissmann, L., Wolnik, L., Ikenberg, H., Koldovsky, U., Schnurch, H. G., and Hausen, H. Z., 1983, Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers, Proc. Natl. Acad. Sci. U.S.A. 80:560–563.
Goldberg, R. M, Ayoob, M., Silgals, R., Ahlgren, J., and Neefe, J. R., 1985, Phase II trial of lymphoblastoid interferon in metastatic malignant melanoma. Cancer Treat. Rep. 69:813–816.
Goldenberg, G. J., Brandes, L. J., Lau, W. H., Miller, A. B., Wall, C., and Ho, J. H. C., 1985, Cooperative trial of immunotherapy for nasopharyngeal caricnoma with transfer factor from donors with Epstein-Barr virus antibody activity. Cancer Treat. Rep. 69:761–767.
Goodman, G. E., Beaumier, P., Hellstrom, I., Femyhough, B., and Hellstrom, K.-E., 1985, Pilot trial of murine monoclonal antibodies in patients with advanced melanoma, J. Clin. Oncol. 3: 340–352.
Grimm, E. A., Mazumder, A., Zhang, H. Z., and Rosenberg, S. A., 1982, Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2- activated autologous human peripheral blood lymphocytes, J. Exp. Med. 155:1823–1841.
Grimm, E. A., Robb, R. J., Roth, J. A., Neckers, L. M., Lachman, L. B., Wilson, D. J., and Rosenberg, S.A., 1983a, Lymphokine-activated killer cell phenomenon: III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells, J. Exp. Med. 158:1356–1361.
Grinmi, E. A., Ramsey, K. M., Mazumder, A., Wilson, D. J., Djeu, J. Y., and Rosenberg, S. A., 1983b, Lymphokine-activated killer cell phenomenon: II. Precursor phenotype is serologically distinct from pheripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells, J. Exp. Med. 157:884–897.
Groopman, J. E., Mitsuyasu, R. T., DeLeo, M. J., Oette, D. H., and Golde, D. W., 1987, Effect of recombinant human granulocyte-macrophage colony stimulating factor on myelopoiesis in the acquired inmiunodeficiency syndrome, N. Engl. J. Med. 317:593–598.
Gusdon, J. P., Jr., Homesley, H. D., Muss, H. B., Heise, E. R., Herbst, G. A., Richards II, F., Spurr, C. L., Lovelace, J. V., and Di Saia, P. J., 1981, Chemotherapy of advanced ovarian epithelial carcinoma with melphalan and levamisole: A pilot study of the Gynecologic Oncology Group, Am. J. Obstet. Gynecol. 141:65.
Haaff, E. O., Catalona, W. J., and Ratliff, T. L., 1986a, Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG, J. Urol. 136: 970–974.
Haaff, E. O., Dresner, S. M., Ratliff, T. L., and Catalona, W. J., 1986b, Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder, J. Urol. 136: 820–824.
Halpem, B. (ed.), 1975, Corynebacterium parvum: Applications in Experimental and Clinical Oncology, Plenum Press, New York.
Harris, D. T., 1983, Hormonal therapy and chemotherapy of renal cell carcinoma, Semin. Oncol. 10: 422–430.
Hawkins, M., Homing, S., Konrad, M., Anderson, S., Sielaff, K., Rosno, S., Schiesel, J., Davis, T., DeMets, D., Merigan, T., and Borden, E., 1985, Phase I evaluation of a synthetic mutant of ß-interferon. Cancer Res. 45:5914–5920.
Hellstrom, I., Hellstrom, K. E., and Shepard, T. H., 1970, Cell-mediated immunity against antigens common to human colonic carcinomas and fetal gut epithelium. Int. J. Cancer 6:346–351.
Hellstrom, I., Garrigues, H. J., Cabasco, L., Mosely, G. H., Brown, J. P., and Hellstrom, K. E., 1983, Studies of a high molecular weight human melanoma-associated antigen, J. Immunol. 130:1467–1472.
Herberman, R. B., and Ortaldo, J. R., 1981, Natural killer cells: Their role in defenses against disease. Science 214:24–30.
Herlyn, D., Lübeck, M., Sears, H., and Koprowski, H., 1985, Specific detection of anti-idiotypic immune responses in cancer patients with murine monoclonal antibody, J. Immunol. Methods 85:27–38.
Herlyn, D., Sears, H., Iliopoulos, D., Lübeck, M., Douillard, J. Y., Sindelar, W., Tempero, M., Mellstedt, H., Maher, M., and Koprowski, H., 1986a, Anti-idiotypic antibodies to monoclonal antibody C017–1A, Hybridoma 5:S51-S58.
Herlyn, D., Ross, A. H., and Koprowski, H., 1986b, Anti-idiotypic antibodies bear the internal image of a human tumor antigen. Science 232:100–102.
Herlyn, D., Wettendorff, M., Schmoll, E., Iliopoulos, D., Schedel, I., Dreikhausen, U., Raab, R., Ross, A. H., Jaksche, H., Scriba, M., and Koprowski, H., 1987, Anti-idiotype immunization of cancer patients: Modulation of the immune response, Proc. Natl. Acad. Sci. U.S.A. 84: 8055–8059.
Herlyn, M., Stepleuski, Z., Heriyn, D., Clark, W. H., Jr., Ross, A. H., Blaszczyk, M., Pak, K. Y., and Koprowski, H., 1983, Production and characterization of monoclonal antibodies against human malignant melanoma. Cancer Invest. 1:215–224.
Herlyn, M., Guerry, D., and Koproski, H., 1985, Recombinant 7-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells, J. Immunol. 134:4226–4230.
Herr, H. W., Pinsky, C. M., Whitmore, W. F., Jr., Sogani, P. G., Oettgen, H. F., and Melamed, M. R., 1985, Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors, Urology 25:119–123.
Herr, H. W. Pinsky, C. M., Whitmore, W. F. Jr., Sogani, P. C., Oettgen, H. F., and Melamed, M. R., 1986, Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder, J. Urol. 135:265–267.
Hersey, P., 1985, Review of melanoma antigens recognized by monoclonal antibodies (MAbs). Their functional significance and applications in diagnosis and treatment of melanoma, Pathology 17:346–354.
Hersey, P., Hasic, E., MacDonald, M., Edwards, A., Spurling, A., Coates, A.S., Milton, G. W., and McCarthy, W. H., 1985, Effects of recombinant leukocyte interferon (rIFN-αA) on tumour growth and immune responses in patients with metastatic melanoma, Br. J. Cancer 51:815–826.
Hersey, P., MacDonald, M., Hall, C., Spuriing, A., Edwards A., Coates, A., and McCarthy, W., 1986, Immunological effects of recombinant interferon alpha-2a in patients with disseminted melanoma, Cancer 57:1666–1674.
Hersh, E. M., Patt, Y. Z., Murphy, S. G., Dicke, K., Zander, A., Adegbite, M., and Goldman, R., 1980, Radiosensitive, thymic hormone sensitive peripheral blood suppressor cell activity in cancer patients. Cancer Res. 40:3134–3140.
Herskovic, A., Bauer, M., Seydel, H. G., Yesner, R., Scotte Doggett, R. L., Pewrez, C. A., Durbin, L. M., and Zinninger, M., 1988, Post-operative thoracic irradiation with or without levamisole in non-small cell lung cancer: Results of a Radiation Therapy Oncology Group study, Int. J. Radiat. Oncol. Biol. Phys. 14:37–42.
Holland, J. M., 1975, Natural history and staging of renal cell carcinoma. Cancer J. Clin. 25:121–133.
Hollinshead, A. C., 1987, Antigenic epitopes of three tumor-associated antigens of well-differentiated squamous cell carcinoma of the larynx for use in monitoring patients in specific active immunochemotherapy trials. Cancer Detect. Prevent. 10:153–158.
Hollinshead, A., Glew, D., Bunnag, B., Gold, P., and Herderman, R., 1970, Skin reactive soluble antigen from intestinal cancer cell membranes and relationship to carcinoembryonic antigens. Lancet 2:1191–1195.
Hollinshead, A., Elias, E. G., Arlen, M., Buda, B., Mosley, M., and Scherrer, J., 1985, Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA): A phase I clinical trial. Cancer 56:480–489.
Holmes, E. C., and Gail, M., 1986, Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma, J. Clin. Oncol. 4:710–715.
Holmes, E. C., Hill, L. D., Gail, M., and The Lung Cancer Study Group, 1985, A randomized comprison of the effects of adjuvant therapy on resected stages II and III non-small cell carcinoma of the lung, Ann. Surg. 202:335–341.
Hong, W. K., and Bromer, R., 1983, Medical intelligence current concepts: Chemotherapy in head and neck cancer, N. Engl. J. Med. 308:75–79.
Hood, A. P., Farmer, E. R., and Weiss, R. A., 1982, Kaposi’s sarcoma, Johns Hopkins Med. J. 151:222–230.
Hooper, J. A., McDaniel, M. C., Thurman, G. B., Cohen, G. H., Schulof, R. S., and Geldstein, A. L., 1975, Purification and properties of bovine thymosin, Ann. N.Y. Acad. Sci. 249: 125–144.
Hoover, H. C., Jr., Surdyke, M. G., Dangel, R. B. Peters, L. C., and Hanna, M. G., Jr., 1985, Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 55:1236–1243.
Houghton, A.N., Mintzer, D., Cordon-Cardo, C., Welt, S., Fliegel, B., Vadhan, S., Carswell, E., Melamed, M. R., Oettgen, H. F., and Old, L. J., 1985, Mouse monoclonal IgG3 antibody detecting Gd3 ganglioside: A phase I trial in patients with malignant melanoma, Proc. Natl. Acad. Sci. U.S.A. 82:1242–1246.
Houghton, A. N., Cordon-Cardo, C., and Eisenger, M., 1986, Differentiation antigens of melanoma and melanocytes. Int. Rev. Exp. Pathol. 28:217–248.
Hrushesky, W. J., and Murphy, G. P., 1977, Current status of the therapy of advanced renal carcinoma, J. Surg. Oncol. 9:277–288.
Hubay, C. A., Pearson, O. H., Manni, A., Gordon, N. H., and McGuires, W. L., 1985, Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6-year result. III. Antiestrogens in combination with chemotherapy in early breast cancer, J. Steroid Biochem. 23:1147–1150.
Humm, J. L., 1986, Dosimetric aspects of radiolabeled antibodies for tumor therapy, J. Nucl. Med. 27:1490–1497.
Ikebuchi, K., Wong, G. G., Clark, S. C., Ihle, J. N., Hirai, Y., and Ogawa, M., 1987, Interleukin6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors, Proc. Natl. Acad. Sci. U.S.A. 84:9035–9039.
Ikic, D., Maricic, Z., Oresic, V., Rode, B., Nola, P., Smidj, K., Knezevic, M., Jusic, D., and Soos, E., 1981, Application of human leukocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma. Lancet 1:1022–1024.
Ikonopisou, R. L., 1975, The use of BCG in the combined treatment of malignant melanoma, in: International Symposium on Immunological Reactions to Melanoma Antigens, Vol. 56 (J. R. Kalden, ed.), Behring-werke, Hanover, pp. 206–214.
Itoh, K., Tilden, A. B., Kumagai, K., and Balch, C. M., 1985, Leu-ll+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (LAK) cells, J. Immunol 134:802–807.
Jacobs, K., Shoemaker, C., Rudersdorf, R., Neill, S. D., Kaufman, R. J., Mufson, A., Seehra, J., Jones, S. S., Hewick, R., Fritsch, E. F., Kawakita, M., Shimizu, T., and Miyake, T., 1985, Isolation and characterization of genomic and cDNA clones of human erythropoetin. Nature 313:806–810.
Jacobs, S. K., Komblith, P. L., Wilson, D. L., and Grimm, E. A., 1986a, In vitro killing of human glioblastoma by interleukin-2 activated autologous lymphocytes, J. Neurosurg. 64:114–117.
Jacobs, S. K., Wilson, D. J., Komblith, P. L., and Grimm, E. A., 1986b, Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma, J. Neurosurg. 64:743–749.
Jacobs, S. K., Wilson, D. J., Komblith, P. L., and Grimm, E. A., 1986c, Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: Phase I trial. Cancer Res. 46:2101–2104.
Jaffers, G., Colvin, R., Cosimi, A., Giorgi, J. V., Goldstein, G., Fuller, T. C., Kumick, J. T., Lillehei, C., and Russell, P. S., 1983, The human immune response to murine OKT3 monoclonal antibody. Transplant Proc. 15:646–648.
Jessup, J. M., 1987, Adjuvant active specific immunotherapy (ASIT) enhances cell mediated immunity to autologous human colorectal carcinoma, Proc. AACR 28:361.
Jessup, J. M., McBride, C. M., Ames, F. C., Guarda, L., Ota, D. M., Romsdahl, M. M., and Martin, R. G., 1986, Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: Comparison of two doses of the vaccine. Cancer Immunol. Immunother. 21:233–239.
Kaminer, B., and Murray, J. F., 1950, Sarcoma idiopathicum multiple haemorrhagicum of Kaposi with special reference to its incidence in the South African Negro, and two case reports, South Afr. J. Clin. Sci. 1:1–25.
Kaufmann, M., Marqverson, J., Stanley, K. E., Mouritzen, C., and Hvid-Hansen, H., 1986, Distribution of intrapleural and intravenous Corynebacterium parvum in humans: 99Tc-, and 131I-labeled bacteria. Cancer Immunol. Immunother. 22:56–61.
Kay, R. G., Mason, B. H., Stephens, E. J. Arthur, J. F., Hitchcock, G. C., Trindall, P. L., Rodgers, R., and Mullins, P., 1983, Levamisole in primary breast cancer: A controlled study in conjunction with l-phenylalanine mustard. Cancer 51:1992–1997.
Kelley, D. R., Ratliff, T. L., Catalona, W. J., Shapiro, A., Lage, J. M., Bauer, W. C., Haaff, E. O., and Dresner, S. M., 1985, Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: Effect of bacillus Calmette-Guerin viability on treatment results, J. Urol. 134: 48–53.
Kelley, D. R., Haaff, E. O., Becich, M., Lage, J., Bauer, W. C., Dresner, S. M., Catalona, W. J., and Ratliff, T. L., 1986, Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin, J. Urol. 135:268–271.
Kempf, R. A., Gmnberg, S. M., Daniels, J. R., Skinner, D. G., Venturi, C. L., Spiegel, R., Neri, R., Greiner, J. M., Rudnick, S., and Mitchell, M. S., 1986, Recombinant interferon a-2 (INTRON A) in a phase II study of renal cell carcinoma, J. Biol. Resp. Mod. 5:27–35.
Khoo, S. K., Whitaker, S. V., Jones, I. S. C., and Thomas, D. A., 1984, Levamisole as adjuvant to chemotherapy of ovarian cancer. Cancer 54:986–990.
Kies, M. S., Levitan, N., and Hong, W. K., 1985, Chemotherapy of head and neck cancer, Otolaryngol. Clin. North Am. 18:533–541.
Kirkwood, J. M., Emstoff, M. S., Davis, C. A., Reiss, M., Ferraresi, R., and Rudnick, S. A., 1985a, Comparison of intramuscular and intravenous recombinant alpha-2 inteferon in melanoma and other cancers, Ann. Intern. Med. 103:32–36.
Kirkwood, J. M., Harris, J. E., Vera, R., Sandler, S., Fischer, D. S., Khandekar, J., Emstoff, M. S., Gordon, L., Lutes, R., Bonomi, P., Lytton, B., Cobleigh, M., and Taylor, S. J., IV, 1985b, A randomized study of low and high doses of leukocyte a-interferon in metastatic renal cell carcinoma: The American Cancer society collaborative trial. Cancer Res. 45:863–871.
Kirsh, M. M., Orringer, M. B., McAuliffe, S., Schork, M. A., Katz, B., and Silva, J. Jr., 1984, Transfer factor in the treatment of carcinoma of the lung, Ann. Thoracic Surg. 38:140–145.
Klefstrom, P., Holsti, P., Grohn, P., Heinonen, E., and Holsti, L., 1985, Levamisole in the treatment of stage II breast cancer: Five-year follow-up of a randomized double-blind study. Cancer 55:2753–2757.
Klefstrom, P., Grohn, P., Heinonen, E., Holsti, L., and Holsti, P., 1987, Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. II. 5-year results and influences of levamisole, Cancer 60:936–942.
Klein, E., 1967, Differential immunologic reactions in normal skin and epidermoid neoplasms. Fed. Proc. 26:430.
Klein, E., 1968, Tumors of the skin. X. Immunotherapy of cutaneous and mucosal neoplasms, N.Y. State J. Med. 68:900–911.
Klein, E., 1969, Hypersensitivity reactions at tumor sites. Cancer Res. 29:2351–2362.
Klein, E., Holtermann, O., Milgrom, H., Case, R. W., Klein, D., Rosner, D., and Djerassi, I., 1976, Immunotherapy for accessible tumors utilizing delayed hypersensitivity reactions and separated components of the immune system, Med. Clin. North Am. 60:389–418.
Kohier, G., and Milstein, C., 1975, Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497.
Korec, S., Smith, F. P., Schein, P. S., and Phillips, T. M., 1984, Clinical experiences with extracorporeal immunoperfusion of plasma from cancer patients, J. Biol. Resp. Mod. 3:330–335.
Komblith, P. L., Walker, M. R., and Cassady, R. J., 1985, Neoplasms of the central nervous system, in: Cancer, Principles and Practice of Oncology (V. T. De Vita, S. Hellman, and A. Rosenberg, eds.), J. B. Lippincott, Philadelphia, pp. 1437–1510.
Krauss, S., Comas, F., Perez, C., Gordon, D., Philpott, G., Broun, G., Mill, W., Robbins, R., Smalley, R., Mendiondo, O., DeSimone, P., McLaren, J., Keller, J., Durant, J., Birch, R., and Buchanan, R., 1984, Treatment of inoperable non-small cell carcinoma of the lung with radiation therapy, with or without levamisole. Am. J. Clin. Oncol. 7:405–412.
Krigel, R., Padavic, K., Comis, R., and Rudolph, A., 1987, A phase I study of recombinant interleukin-2 plus recombinant beta-interferon, Proc. ASCO 6:238.
Krown, S. E., 1987, Interferon treatment of renal cell carcinoma, Cancer 59:647–651.
Krown, S. E., Real, F. X., Cunningham-Rundles, S., Myskowski, P. L., Koziner, B. Fein, S., Mittelman, A., Oettgen, H. F., and Safai, B., 1983, Preliminary observations of the effect of recombinant leukocyte A interferon in homosexual men with Kaposi’s sarcoma, N. Engl. J. Med. 308:1071–1076.
Krown, S. E., Burk, M. W., Kirkwood, J. M., Kerr, D., Morton, D. L., and Oettgen, H. F., 1984, Human leukocyte (alpha) inteferon in metastatic malignant melanoma: The American Cancer Society phase II trial. Cancer Treat. Rep. 68:723–726.
Krown, S. E., Real, F. X., Vadhan-Raj, S., Cunningham-Rundles, S., Krim, M., Wong, G., and Oettgen, H. F., 1986, Kaposi’s sarcoma and the acquired inmiune deficiency syndrome: Treatment with recombinant interferon alpha and analysis of prognostic factors. Cancer 57:1662–1665.
Krown, S. E., Mintzer, D., Cunningham-Rundles, S., Niedzwiecki, D., Krim, M., Einzig, A. I., Gabrilove, J. L., Shurgot, B., and Gessula, J., 1987, High-dose human lymphoblastoid inter- feron in metastatic colorectal cancer: Clinical results and modification of biological responses, Cancer Treat. Rep. 71:39–45.
Lafreniere, R., and Rosenberg, S. A., 1985a, Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2, Cancer Res. 45:3735–3741.
Lafreniere, R., and Rosenberg, S. A., 1985b, Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma, J. Immunol. 135:4273–4280.
Lamm, D. L., 1985, Bacillus Calmette-Guerin immunotherapy for bladder cancer, 7. Urol. 134: 40–47.
Lamm, D. L., Thor, D. E. Stogdill, V. D., and Radwin, H. M., 1982, Bladder cancer immunotherapy, J. Urol. 128:931–935.
Lamm, D. L., Stogdill, V. D., Stogdill, B. J., and Crispen, R. G., 1986, Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer, J. Urol. 135:272–274.
Larrick, J. W., and Bouria, J. M., 1986, Prospects for the therapeutic use of human monoclonal antibodies, J. Biol. Resp. Mod. 5:379–393.
Larson, S. M., Brown, J. P. Wright, P. W., Carrasquillo, J. A., Hellstrom, I., and Hellstrom, K. E., Imaging of melanoma with 131I labelled monoclonal antibodies, J. Nucl. Med. 24:123- 129.
Laurie, J., Moertel, C., Fleming, T., Wieand, H., Leigh, J., Beart, R., Cullinan, S., and Krook, J., 1987, Surgical adjuvant therapy of poor prognosis colorectal cancer with levamisole alone or combined levamisole and 5-fluorouracil (5-FU), Proc. ASCO 5:81.
Lederer, E., and Chedid, L., 1982, Immunomodulation by synthetic muramyl peptides and trehalose diesters, in: Immunologic Approaches to Cancer Therapeutics (E. Mihich, ed.), John Wiley & Sons, New York, pp. 107–136.
Legha, S. S., Papadopoulas, N. E. J., Plager, C., Ring, S., Chawla, S. P., Evans, L. M., and Benjamin, R. S., 1987, Clinical evaluation of recombinant interferon alpha-2a (Roferon-A) in metastatic melanoma using two different schedules, J. Clin. Oncol. 5:1240–1246.
Levy, R., 1987, Editorial: Will monoclonal antibodies find a place in our therapeutic armamentarium? J. Clin. Oncol. 5:527–529.
Lichtenstein, A., Tuttle, R., Cantrell, J., and Zighelboim, J., 1982, Effects of different fractions of Corynebacterium parvum on the cytotoxic T-cell response to alloantigens in mice, J. Natl. Cancer Inst. 69:495–501.
Lichtenstein, A., Berek, J., Bast, R., Spina, C., Hacker, N., Knapp, R. C., and Zighelboim, J., Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum, J. Biol. Resp. Mod, 3:371–378.
Livingston, P. O., Albino, A. P., Chung, T. J. C., Real, F. X., Houghton, A. N., Gettgen, H. F., and Old, L. J., 1985, Serological responses of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 55:713–720.
Livingston, P. O., Natoli, E. J., Calves, M. J., Stocken, E., Oettgen, H. F., and Old., L. J., 1987, Vaccines containing purified Gm2 ganglioside elicit Gm2 antibodies in melanoma patients, Proc. Natl. Acad. Sci. U.S.A. 84:2911–2915.
Lonberg, M., Odajnyk, C., Krigel, R., Laubenstein, L., Wemz, J., Green, M., and Muggia, F., Sequential and simultaneous alpha 2 interferon (IFN) and VP-16 in epidemic Kaposi’s sarcoma (EKS), Proc. ASCO 4:2.
Lotze, M. T., Grimm, E. A., Mazumder, A., Strausser, J. L., and Rosenberg, S. A., 1981, Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor, Cancer Res. 41:4420–4425.
Lotze, M. T., Carrasquillo, J. A., Weinstein, J. N., Bryant, G. J., Perentesis, P., Reynolds, J. C., Matis, L. A., Eger, R. R., Keenan, A. M., Hellstrom, I., Hellstrom, K. E., and Larson, S. M.,1986, Monoclonal antibody imaging of human melanoma:Radioimmunodetection by subcutaneous or systemic injection, Ann. Surg. 204:223–235.
Lotzova, E., 1987, Interleukin-2-generated killer cells, their characterization and role in cancer therapy. Cancer Bull. 39:30–38.
Ludwig Lung Cancer Study Group, 1985, Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung, J. Thorac. Cardiovasc. Surg. 89:842–847.
Ludwig Lung Cancer Study Group, 1986, Intrapleural and intravenous Corynebacterium parvum in patients with resected stage I and II non-small cell carcinoma of the lung. Cancer Immunol. Immunother. 23:1–4.
Lundell, G., Blomgren, H., Cedermark, B., Silfversward, C., Theve, T., and Ohman, U., 1984, High dose rDNA human alpha2 interferon therapy in patients with advanced colorectal adenocarcinoma: A phase II study, Radiother. Oncol. 1:325–332.
Lundquist, P.-G., Haglund, S., Carlsoo, B., Strander, H., and Lundgren, E., 1984, Interferon therapy in juvenile laryngeal papillomatosis, Otolaryngol. Head Neck Surg. 92:386–391.
Magnus, K., 1977, Incidence of malignant melanoma of the skin in the five Nordic countries: Significance of solar radiation, Int. J. Cancer 20:477–485.
Mahaley, M. S., Jr., Urso, M. B., Whaley, R. A., Blue, M., Williams, T. E., Guaspari, A., and Selker, R. G., 1985, Immunobiology of primary intracranial tumors. Part 10: Therapeutic efficacy of interferon in the treatment of recurrent gliomas, J. Neurosurg. 63:719–725.
Mansell, P. W. A., Ichinose, H., and Reed, R. J., 1975, Macrophage mediated destruction of human malignant cells in vivo, J. Natl. Cancer Inst. 54:571–580.
Mark, D., Brummond, R., Creasey, A., Lin, L., Khosrovi, B., Edwards, B., Groverman, D., Joseph, J., Hawkins, M., and Borden, E., 1983, A synthetic mutant of interferon beta for clinical trial, in: Interferons, Proceedings of the International Symposium on Interferons (T. Koshida ed.), Kyoto Prefectural University of Medicine, Kyoto, pp. 167–172.
Mark, D. P., Lu, S. D., Creasey, A. A., Yamamoto, R., and Lyn, L. S., 1984, Site specific mutagenesis of the human fibroblast interferon gene, Proc. Natl. Acad. Sci. U.S.A. 81:5662–5666.
Marshall, V. F., 1952, The relation of the preoperative estimate to the pathologic demonstration of the extent of vesical neoplasms, J. Urol. 68:714.
Martin, D. S., Hayworth, P., Fugmann, R. H., English, R., and McNeill, H. W., 1964, Combination therapy with cyclophosphamide and zymosan on a spontaneous mammary cancer in mice. Cancer Res. 24:652–654.
Marumo, K., Murai, M., Hayakawa, M., and Tazaki, H., 1984, Human lymphoblastoid interferon therapy for advanced renal cell carcinoma. Urology 24:567–571.
Mastrangelo, M. J., Baker, A. R., and Katz, H. R., 1985, Cutaneous Melanoma, in: Cancer, Principles and Practice of Oncology (V. T. Devita, S. Hellman, and S. H. Rosenberg, eds.), J. B. Lippincott, Philadelphia, pp. 1371–1422.
Matthay, R. A., Mahler, D. A., Beck, G. J., Loke, J., Baue, A. E., Carter, D. C., and Mitchell, M. S., 1986, Intratumoral bacillus Calmette-Guerin immunotherapy prior to surgery for carcinoma of the lung: Results of a prospective randomized trial. Cancer Res. 46:5963–59-68.
Maurer, L. H., Pajak, T., Eaton, W., Comis, R., Chahinian, P., Faulkner, C., Silberfarb, P. M., Henderson, E., Rege, V. B., Balkwin, P. E., Weiss, R., Rafla, S., Prager, D., Carey, R., Perry, M., and Choi, N. C., 1985, Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: A phase III cancer and leukemia group B study, J. Clin. Oncol. 3:969–976.
McLaughlin, C. A., Schwartzman, S. M., Homer, B. L., Jones, G. H., Moffatt, J. G., Nestor, J. J., Jr., and Tegg, D., 1980, Regression of tumors in guinea pigs after treatment with synthetic muramyl dipeptides and trehalose dimycolate. Science 208:415–416.
McLeod, D. T., Calverley, P. M. A., Millar, J. W., and Home, N. W., 1985, Further experience of Corynebacterium parvum in malignant pleural effusion. Thorax 40:515–518.
McLeod, G. R. C., Thomson, D. B., and Hersey, P., 1987, Recombinant interferon alpha-2a in advanced malignant melanoma. A phase I-II study in combination with DTIC, Int. J, Cancer (Suppl.) 1:31–35.
Medina, J. E., 1983, Commentary: The controversial role of BCG in the treatment of squamous cell carcinoma of the head and neck, Arch. Otolaryngol. 109:543.
Merguerian, P. A., Donahue, L., and Cockett, A. T. K., 1987, Intraluminal interleukin 2 and bacillus Calmette-Guerin for treatment of bladder cancer: A preliminary report, J. Urol. 137: 216–219.
Messerschmidt, G. L., Bowles, C. A., Henry, D. H., and Deisseroth, A. B., 1984, Clinical trials with Staphylococcus aureus and protein A in the treatment of malignant disease, J. Biol. Resp. Mod. 3:325–329.
Messerschmidt, G. L., Henry, D. H., Synder, J., Bertram, J., Mittelman, A., Ainsworth, S., Fiore, J., Viola, M. v., Louie, J., Ambinder, E., MacKintosh, F. R., Higby, D. J., O’Brien, P., Kiprov, D., Hamburger, M., Balint, J. P., Jr., Fisher, L. D., Perkins, W., Pinsky, C. M., and Jones, F. R., 1988, Protein A immunoadsorption in the treatment of malignant disease, J. Clin. Oncol. 6:203–212.
Metcalf, D., 1986, Review: The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood 67:257–267.
Millar, J. W., Huuter, A. W., and Home, N. W., 1980, Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions. Thorax 35:856–858.
Mitchell, M. S., Kempf, R. A., Harel, W., Shau, H., Boswell, W. D., Lind, S., and Bradley, E. C., 1988, Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 disseminated melanoma, J. Clin. Oncol. 6:409–424.
Montie, J., Stewart, B. H., Straffon, R. A., Banowsky, L. H. W., Hewitt, C. B., and Montague, D. K., 1977, The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma, J. Urol 117:272.
Morales, A., 1980, Treatment of carcinoma in situ of the bladder with BCG: A phase II trial. Cancer Immunol. Immunother. 9:69–72.
Morales, A., 1984, Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer, J. Urol. 132:457–459.
Morales, A., Eidinger, D., and Bruce, A. W., 1976, Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors, J. Urol. 116:180–183.
Mori, K., Lamm, D. L., and Crawford, E. D., 1986, A trial of bacillus Calmette-Guerin versus adriamycin in superficial bladder cancer: A South-West Oncology Group study, Urol. Int. 41: 254–259.
Morton, D. L., 1971, Immunological studies with human neoplasms, J. Reticuloendothel. Soc. 10: 137–160.
Morton, D. L., Eilber, F. R., Malmgren, R. A., and Wood, W. C., 1970, Immunological factors which influence response to immunotherapy in malignant melanoma, Surgery 68:158–164.
Morton, D. L., Eiliber, F. R., Holmes, E. C., Hunt, J. S., Ketcham, A. S., Silverstein, M. J., and Sparks, F. C., 1974, BCG immunotherapy of malignant melanoma: Summary of a seven year experience, Ann. Surg. 180:635–643.
Mulé, J. J., Shu, S., Schwarz, S. L., and Rosenberg, S. A., 1984, Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225; 1487–1489.
Mulé, J. J., Shu, S., and Rosenberg, S. A., 1985, The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo, J. Immunol. 135:646–652.
Mulé, J. J., Smith, C. A., and Rosenberg, S. A., 1987, Interleukin-4 (B-cell stimulatory factor 1) can mediate the induction of LAK activity directed against fresh tumor cells, J. Exp. Med. 166: 792–797.
Murray, J. L., Rosenblum, M. G., Sobol, R. E., Bartholomew, R. M., Plager, C E., Haynie, T. P., Johns, M. F., Glenn, H. J., Lamki, L., Benjamin, R. S., Papadopoulos, N., Boddie, A. W., Frincke, J. M., David, G. S., Carlo, D. J., and Hersh, E. M., 1985, Radioimmunoimaging in malginant melanoma with 111Un-Iabeled monoclonal antibody 96.5, Cancer Res. 45:2376–2381.
Murray, J. L., Rosenblum, M. G., Lamke, L., Haynie, T. P., Glenn, H. J., Plager, C. E., Unger, M. W., Carlo, D. J., and Hersh, E. M., 1987a, Radioimmunoimaging in malignant melanoma patients with the use of indium-lll-labeled antimelanoma monoclonal antibody (ZME-018) to high-molecular-weight antigen, Natl. Cancer Inst. Monogr. 3:3–9.
Murray, J. L., Rosenblum, M. G., Lamki, L., Glenn, H. J., Krizan, Z., Hersh, E. M., Plager, C. E., Bartholomew, R. M., Unger, M. W., Carlo, D. J., 1987b, Clinical parameters related to optimal tumor localization of indium-lll-labeled mouse antimelanoma monoclonal antibody ZME-018, J. Nucl. Med. 28:25–33.
Muss, H. B., Kempf, R. A., Martino, S., Rudnick, S. A., Greiner, J., Cooper, M. R., Decker, D., Grunberg, S. M., Jackson, D. V., Richars, F. II, Sarnal, B., Singhakowinta, A., Spurr, C. L., Stuart, J. J., White, D. R., Caponera, M., and Mitchell, M. S., 1984, A phase II study of recombinant a interferon in patients with recurrent or metastatic breast cancer, J. Clin. Oncol. 2:1012–1016.
Muss, H. B., Costanzi, J. J., Leavitt, R., Williams, R. D., Kempf, R. A., Pollard, R., Ozer, H., Zekan, P. J., Grunberg, S. M., Mitchell, M. S., Caponera, M., Gavigan, N., Ernest, M. L., Venturi, C., Greiner, J., and Spiegel, R. J., 1987, Recombinant alpha interferon in renal cell carcinoma: A randomized trial of two routes of administration, J. Clin. Oncol. 5:286–291.
Myers, G. H., Fehrenbaker, L. G., and Kelalis, P. P., 1968, Prognostic significance of renal vein invasion by hypernephroma, J. Urol. 100:420.
Naclerio, R., 1985, Recent advances in immunology with specific reference to otolaryngology, Otolaryngol. Clin. North Am. 18:821–831.
Nagai, M., and Arai, T., 1984, Clinical effect of interferon in malignant brain tumors, Neurosurg. Rev. 7:55–64.
Natali, P. G., Cavaliere, R., Bigotti, A., Nicotra, M. R., Russo, C., Ng, A. K., Giacomini, P., and Ferrone, S., 1983, Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions, J. Immunol. 130:1462–1466.
National Institutes of Health Consensus Development Panel on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer, 1986, Introduction and conclusions. Adjuvant chemotherapy and endocrine therapy for breast cancer, Natl. Cancer Inst. Monogr. 1:1–4.
Neidhart, J. A., 1986, Interferon therapy for the treatment of renal cancer. Cancer 57:1696–1699.
Neidhart, J. A., Gagen, M. M., Young, D., Tuttle, R., Melink, T. J., Ziccarrelli, A., and Kisner, D., 1984, Interferon-a therapy of renal cancer, Cancer Res. 44:4140–4143.
Neifeld, J. P., Terz, J. J., Kaplan, A. M., and Lawrence, J. W., 1985, Adjuvant Corynebacterium parvum immunotherapy for squamous cell epitheliomas of the oral cavity, pharynx, and larynx, J. Surg. Oncol. 28:137–145.
Newbill, E. T., and Johns, M. E., 1983, Immunology of head and neck cancers, CRC Crit. Rev. Clin. Lab. Sci. 19:1–25.
Nicola, N. A., Metcalf, D., Matsumoto, M., and Johnson, G. R., 1983, Purification of a factor- inducing differentiation in murine myelomonocytic leukemia cells, J. Biol. Chem. 258:9017–9023.
Niloff, J. M., Knapp, R. C., Jones, G., Schaetzl, E. M., Bast, R. C. Jr., 1985, Recombinant leukocyte alpha interferon in advanced ovarian carcinoma. Cancer Treat. Rep. 69: 895–896.
North, R. J., 1982, Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T-cells, J. Exp. Med. 55:1063–1074.
Obbens, E. A. M. T., Feun, L. G., Leavens, M. E., Savaraj, N., Stewart, D. J., and Gutterman, J. U., 1985, Phase I clinical trial of intralesional or intraventricular leukocyte interferon for intracranial malignancies, J. Neurooncol. 3:61–67.
Oberg, K., Norheim, L, Lind, E., Aim, G., Lundqvist, G., Wide, L., Jonsdottir, B., Magnusson, A., and Wilander, E., 1986, Treatment of malignant carcinoid tumors with human leukocyte interferon: Long-term results, Cancer Treat. Rep. 70:1297–1304.
Odajnyk, C., and Franco, F. M., 1985, Treatment of Kaposi’s sarcoma: Overview and analysis by clinical setting, J. Clin. Oncol. 3:1277–1285.
Oettgen, H., Old, L., Farrow, J., Valentine, F. T., Lawrence, H. S., and Thomas, L., 1974, Effects of dialyzable transfer factor in patients with breast cancer, Proc. Natl. Acad. Sci. 71:2319–2323.
Oldham, R., Weese, J. L., Herberman, R. B., Perlin, E., Mills, M. N., Heims, W., Blom, J., Green, D., Reid, J., Bellinger, S., Law, I., McCoy, J. L., Dean, J. H., Cannon, G. B., and Djeu, J., 1976, Immunologic monitoring and immunotherapy of carcinoma of the lung. Int. J. Cancer 18:739.
Oldham, R. K., Foon, K. A., Morgan, A. C., Woodhouse, C. S., Schroff, R. W., Abrams, P. G., Fer, M. N., Schoenberger, C. S., Farrell, M., Kimball, E., and Sherwin, S. A., 1984, Monoclonal antibody therapy of malignant melanoma: In vivo localization in cutaneous metastasis after intravenous administration, J. Clin. Oncol. 2:1235–1244.
Olsson, L., and Kaplan, H. S., 1980, Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity, Proc. Natl. Acad. Sci. U.S.A. 77:5429–5431.
Oyama, K., Takagaki, Y., and Niki, R., 1975, Studies on the interrelation between clinical effects and immune response of a streptococcal antitumor agent OK 432, Jpn. J. Clin. Cancer 21:253.
Padmanabhan, N., Balkwill, F. R., Bodmer, J. G., and Rubens, R. D., 1985, Recombinant DNA human interferon alpha 2 in advanced breast cancer: A phase 2 trial, Br. J. Cancer 51:55–60.
Padmanabhan, T. K., Balaram, P., and Vasudevan, D. M., 1987, Role of levamisole immunotherapy as an adjuvant to radiotherapy in oral cancer. I. A three-year clinical follow up, Neoplasma 34:627–632.
Panettiere, F. J., and Chen, T. T., 1981, Analysis of 626 patients entered on the SWOG large bowel adjuvant program, in: Proceedings of the Third International Conference on the Adjuvant Therapy of Cancer, (S. E. Salmon and S. E. Jones, eds.), Grune and Stratton, New York, pp. 539–546.
Papa, M. Z., Yang, J. C., Vetto, J. T., Shiloni, E., Eisenthal, A., and Rosenberg, S. A., 1988, Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors, Cancer Res. 48:122–129.
Paterson, A. H. G., Willans, D. J., Jerry, L. M., Hanson, J., and McPherson, T. A., 1984, Adjuvant BCG immunotherapy for malignant melanoma. Can. Med. Assoc. J. 131:744–748.
Paul, W. E., and Ohara, J., 1987, B-cell stimulatory factor-1/interleukin 4, Anna. Rev. Immunol. 5: 429–459.
Paulnock, D. M., and Borden, E. C., 1985, Modulation of immune functions by interferons, in: Immunity to Cancer, (A. W. Reif and M. Mitchell, eds.). Academic Press, New York, pp. 545–559.
Pellegrino, M. A., Ng, A.-K., Russo, C., and Ferrone, S., 1982, Heterogenous distribution of the determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. Transplantation 34:18–23.
Phillips, J. H., and Lanier, L. L., 1986, Dissection of the lymphokine-activated killer phenomenon: Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis, J. Exp. Med. 164:814–825.
Pilch, Y. H., Veltman, L. L., and Kern, D. H., 1974, Immune cytolysis of human tumor cells mediated by xenogenic “immune” RNA: Implications for inmiunotherapy. Surgery 76:23–34.
Pimm, M. V., 1987, Immunoscintigraphy: Tumor detection with radiolabeled antitumor monoclonal antibodies, in: Immunology of Malignant Diseases (V. S. Byers and R. W. Baldwin, eds.), MTP Press, Lancaster, pp. 21–43.
Pimm, M. V., Perkins, A. C., Armitage, N. C., and Baldwin, R. W., 1985, The characteristics of blood bom radiolabels and the effect of anti-mouse IgG antibodies on localization of radiolabeled monoclonal antibody in cancer patients, J. Nucl. Med. 26:1011–1023.
Pinsky, C. M., Hirshaut, Y., Wanebo, H. J., Fortner, J. G., Mike, V., Schottenfeld, D., and Oettgen, H. F., 1976, Randomized trial of bacillus Calmette Guerin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage II melanoma, Ann. N.Y. Acad. Sci. 277:187–194.
Pinsky, C. M., Camacho, F. J., Kerr, D., Geller, N. L., Klein, F. A., Herr, H. A., Whitmore, W. F., Jr., and Oettgen, H. F., 1985, Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: Report of a prospective, randomized trial. Cancer Treat. Rep. 69:47–53.
Pizza, G., Severini, G., Menniti, D., de Vinci, C., and Corrado, F., 1984, Tumour regression after intralesional injectin of interleukin 2 (IL-2) in bladder cancer. Preliminary report, Int. J. Cancer 34:359–367.
Plowman, G. D., Brown, J. P., Enns, C. A., Schroder, J., Nikinmaa, B., Sussman, H. H., Hellstrom, K. E., and Hellstrom, I., 1983, Assignment of the gene for human malanoma- associated antigen p97 to chromosome 3, Nature 303:70–72.
Prout, G. R., 1973, The kidney and ureter, in: Cancer Medicine (J. F. Holland and E. Frei, eds.). Lea & Febiger, Philadelphia, pp. 1655–1699.
Quesada, J. R. Swanson, D. A., Trindade, A., and Gutterman, J. U., 1983, Renal cell carcinoma: Antitumor effects of leukocyte interferon. Cancer Res. 43:940–947.
Quesada, J. R., Rios, A., Swanson, D., Trown, P., and Gutterman, J. U., 1985a, Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma, J. Clin. Oncol. 3: 1522–1528.
Quesada, J. R., Swanson, D. A., and Gutterman, J. U., 1985b, Phase II study of interferon alpha in metastatic renal-cell carcinoma: A progress report, J. Clin. Oncol. 3:1086–1092.
Quesada, J. R., Kurzrock, R., Sherwin, S. A., and Gutterman, J. U., 1987, Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma, J. Biol. Resp. Mod. 6: 20–27.
Rambaldi, A., Introna, M., Colotta, F., Landolfo, S., Colombo, N., Mangioni, C., and Mantovani, A., 1985, Intraperitoneal administration of interferon ß in ovarian cancer patients. Cancer 56: 294–301.
Real, F. X., Oettgen, H. F., and Krown, S. E., 1986, Kaposi’s sarcoma and the acquired immunodeficiency syndrome: Treatment with high and low doses of recombinant leukocyte A interferon, J. Clin. Oncol. 4:544–551.
Reid, J. W., Cannon, G. B., Perlin, E., Blom, J., Connor, R., and Herberman, R. B., 1982, Immunologically defined prognostic subgroups as predictors of response to BCG immunotherapy, Recent Res. Cancer Res. 80:219–226.
Retsas, S., Priestman, T. J., Newton, K. A., and Westbury, G., 1983, Evaluation of human lymphoblastoid interferon in advanced malignant melanoma, Cancer 51:273–276.
Revel, M., Kimchi, A., Shulman, L., Shuster, R., Yakobson, E., Chemajovsky, Y., Schmidt, A., Shure, A., and Bendori, R., 1980, Role of interferon-induced enzymes in the antiviral and antimitogenic effects of interferon, Ann. N.Y. Acad. Sci. 350:459–472.
Richardson, G. S., Scully, R. E., Nikrui, N., and Nelson, J. H., 1985, Common epithelial cancer of the ovary, N. Engl. J. Med. 312:415, 474.
Richie, J., Shipley, W. U., and Yagoda, A., 1985, Cancer of the bladder, in: Cancer, Principles and Practice of Oncology (V. T. Devita, S. Hellman, and S. T. Rosenberg, eds.), J. B. Lippincott, Philadelphia, pp. 915–928.
Richman, S. P., Livingston, R. S., Gutterman, J. U., Suen, J. Y., and Hersh, E. M., 1976, Chemotherapy versus chemoimmunotherapy of head and neck cancer: Report of a randomized study. Cancer Treat. Rep. 60:535–539.
Rinehart, J., Malspeis, L., Young, D., and Neidhart, J., 1986a, Phase I/II trial of human recombinant β-interferon serine in patients with renal cell carcinoma. Cancer Res. 46:5364–5367.
Rinehart, J. J., Malspeis, L., Young, D., and Neidhart, J. A., 1986b, Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma, J. Biol. Resp. Mod. 5:300–308.
Rios, A., Mansell, P. W. A., Newell, G. R., Reuben, J. M., Hersh, E. M., and Gutterman, J. U., 1985a, Treatment of acquired immunodeficiency syndrome-related Kaposi’s sarcoma with lym- phoblastoid interferon, J. Clin. Oncol. 3:506–512.
Rios, P., Marsell, G., and Reuben, J., 1985b, The use of lymphoblastoid interferon Hu IFNα (Ly) and vinblastine in the treatment of acquired immune deficiency syndrome (AIDS) related Kaposi’s sarcoma (KS), Proc. ASCO 4:6.
Robinson, E., Haim, N., Segal, R., Veseley, Z., and Mekori, T., 1985, Combined-modality treatment of inoperable lung cancer (iv immunotherapy, chemotherapy, and radiotherapy). Cancer Treat. Rep. 69:251–258.
Robinson, W. A., Mughal, T. I., Thomas, M. R., Johnson, M., and Spiegel, R. J., 1986, Treatment of metastatic malignant melanoma with recombinant interferon alpha 2, Immunobiology 172: 275–282.
Robustelli della Cuna, G., Pavesi, L., Knerich, R., Preti, P., and Paoletti, P., 1984, Radiochemo- immunotherapy (CCNU plus levamisole) for treatment of metastatic brain tumors. A pilot study, J Neuro-Oncol 2:237–240.
Roitt, I. M., Thanavala, Y. M., Mule, D. K., and Huy, F. C., 1985, Anti-idiotypes as surrogate antigens: Structural considerations, Immunol. Today 6:265–261.
Romics, I., Horvath, J., Feher, J., and Csontai, A., 1985, Effect of levamisole on cellular and humoral immune reactivity and on recurrences in patients with bladder papilloma, Int. Urol. Nephrol. 17:323–330.
Rosenberg, S. A., 1988, Editorial: Cancer therapy with interieukin-2: Immunologic manipulations can mediate the regression of cancer in humans, J. Clin. Oncol. 6:403–406.
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., Scipp, C. A., Simpson, C., and Reichert, C. M., 1985a, Observations on the systemic administration of autologous lympho- kine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N. Engl. J. Med. 313:1485–1492.
Rosenberg, S. A., Mule, J. J., Spiess, P. J., Reichert, C. M., and Schwarz, S. L., 1985b, Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant lL-2, J. Exp. Med. 161:1169–1188.
Rosenberg, S. A., Spiess, P., and Lafreniere, R., 1986, A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 233:1318–1321.
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Scipp, C. A., Simpson, C. G., and White, D. E., 1987, A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, N. Engl. J. Med. 316:889–897.
Rossi, G. A., Felletti, R., Balbi, B., Sacco, O., Cosulich, E., Risso, A., Melioli, G., and Ravazzoni, C., 1987, Symptomatic treatment of recurrent malignant pleural effusions with intrapleurally administered Corynebacterium parvum: Clinical response is not associated with evidence of enhancement of local cellular-mediated immunity. Am. Rev. Respir. Dis. 135:885–890.
Rosso, R., Nobile, M. T., Sertoli, M. R., Giannitelli, A., Santi, P. L., Volpe, R., and Nicolo, G., 1985, Antitumoral activity of human fibroblast interferon administered intranodularly. Oncology 42:86–88.
Roszkowski, K., Nozdryn-Plotnicki, B., Roszkowski, W., Ko, H. L., Jeljaszewicz, J., and Pulverer, G., 1985, Small-cell lung cancer and immunochemotherapy with Propionibacterium granulosum KP 45, J. Cancer Res. Clin. Oncol. 109:72–77.
Roth, J. A., Grimm, E. A., Guptol, R. K., and Ames, R. S., 1982, Immunoregulatory factors derived from human tumors: Immunologic and biochemical characterization of factors that suppress lymphocyte proliferative and cytotoxic responses in vitro, J. Immunol. 128:1955–1962.
Rowland, G. F., Axton, C. A., Baldwin, R. W., Brown, J. P., Corvalan, J. R. F., Embleton, M. J., Gore, V. A., Hellstrom, L, Hellstrom, K. E., Jacobs, E., Marsden, C. H., Pimm, M. V., Sinmionds, R. G., and Smith, W., 1985, Antitumor properties of vindesine-monoclonal antibody conjugates. Cancer Immunol. Immunother. 19:1–7.
Rubin, B. Y., and Gupta, S. L., 1980, Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents, Proc. Natl. Acad. Sci. U.S.A. 77:5928–5932.
Sadoughi, N., Mlsna, J., Guinau, P., and Rubenstone, A., 1982, Prognostic value of cell surface antigens using inmiunoperoxidase methods in bladder carcinoma. Urology 20:143–146.
Sahasrabudhe, D. M., deKemion, J. B., Pontes, J. E., Ryan, D. M., O’Donnell, R. W., Maarquis, D. M., Mudholkar, G. S., and McCune, C. S., 1986, Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma, J. Biol. Resp. Mod. 5:581–594.
Sarna, G. P., and Figlin, R. A., 1985, Phase II trial of α-lymphoblastoid interferon given weekly as treatment of advanced breast cancer, Cancer Treat. Rep. 69:547–549.
Sarna, G., Pertcheck, M., Figlin, R., and Ardalan, B., 1986, Phase I study of recombinant β ser 17 interferon in the treatment of cancer, Cancer Treat. Rep. 70:1365–1372.
Sarna, G., Figlin, R., and de Kemion, J., 1987, Interferon in renal cell carcinoma: The UCLA experience. Cancer 59:610–612.
Schantz, S. P., Skolnik, E. M., and O’Neill, J. V., 1980, Improved survival associated with postoperative wound infection in laryngeal cancer: An analysis of its therapeutic implications, Otolaryngol. Head Neck Surg. 88:412–417.
Schellhammer, P. F., Ladaga, L. E., and Fillion, M. B., 1986, Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder, J. Urol. 135:261–264.
Schiller, J. H., Storer, B., Willson, J. K. V., and Borden, E. C., 1987, Phase II trial of combined recombinant beta and gamma interferons in patients with advanced malignant melanoma, Proc. ASCO 6:244.
Schreiber, M. M., Bozzo, P. D., and Moon, T. E., 1981, Malignant melanoma in Southem Arizona, Arch. Dermatol. 117:6–11.
Schreml, W., Lang, M., Betzler, M., Schlag, P., Lohrmann, H. P., Heimpel, H., and Herfarth, C., 1983, Adjuvant chemo(immuno-)-therapy of primary breast cancer with adriamycin- cyclophosphamide (and levamisole)—six-year evaluation, Eur. J. Cancer Clin. Oncol. 19: 607–613.
Schulof, R. S., Simon, G. L., Sztein, M. B., Parenti, D. M., DiGioia, R. A., Courtless, J. W., Orenstein, J. M., Kessler, C. M., Kind, P. D., Schlesselman, S., Paxton, H. M., Robert- Guroff, M., Naylor, P. H., and Goldstein, A. L., 1986, Phase I/II trial of thymosin fraction 5 and thymosin alpha one in HTLV-III seropositive subjects, J. Biol. Resp. Mod. 5:429–443.
Scorticatti, C. H., LaPena, N. C., Bellora, O. G., Mariotto, R. A., Casabe, A. R., and Comolli, R., 1982, Systemic IFN-alpha treatment of multiple papilloma grade I or II patients: Pilot study, J. Interferon Res. 2:339–343.
Scott, M. T., 1974, Corynebacterium parvum as a therapeutic antitumor agent in mice, J. Natl. Cancer Inst. 53:861–865.
Scully, C., 1983, Immunology and oral cancer, Br. J. Oral. Surg. 21:136–146.
Sears, H. F., Herlyn, D., Steplewski, Z., and Koprowski, H., 1985, Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res. 45: 5910–5913.
Sell, S. (ed.), 1980, Cancer Markers, Diagnositic and Developmental Significance, Humana Press, Clifton, NJ.
Sell, S., 1982, Hepatocellular carcinoma markers, in: Human Cancer Markers (S. Sell and B. Wahren, eds.), Humana Press, Clifton, NJ, pp. 133–164.
Sen, G. C., 1984, Biochemical pathways in interferon action, Pharmacol. Ther. 24:235–257.
Sertoli, M. R., Guameri, D., Rubagotti, A., Porcile, G., Nobile, M. T., and Rosso, R., 1987, Adjuvant immunochemotherapy in colorectal cancer Dukes C, Oncology 44:78–81.
Sharpless, G. R., Davies, M. C., and Cox, H. R., 1950, Antagonistic action of certain neurotropic viruses toward a lymphoid tumor in chickens with the resulting immunity, Proc. Soc. Exp. Biol. Med. 73:270–275.
Shawler, D., Bartholomew, R., Smith, L., and Dillman, R., 1985, Human immune response to multiple injections of murine monoclonal IgG, J. Immunol. 135:1530–1535.
Shibata, S., Mori, K., Moriyama, T., Tanaka, K., and Moroki, J., 1987, Randomized controlled study of the effect of adjuvant immunotherapy with picibanil on 51 malignant gliomas, Surg. Neurol. 27:259–263.
Shiloni, E., Eisenthal, A., Sachs, D., and Rosenberg, S. A., 1987, Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2, J. Immunol. 138:1992–1998.
Shively, J. E., and Todd, C. W., 1980, Carcinoembryonic antigen A: Chemistry and biology, in: Cancer Markers, Diagnostic and Developmental Significance (S. Sell, ed.), Humana Press, Clifton, NJ, pp. 295–314.
Shu, S., Chou, T., and Rosenberg, S. A., 1987, Generation from tumor bearing mice of lymphocytes with in vivo therapeutic efficacy, J. Immunol. 139:295–304.
Silgals, R. M., Ahlgren, J. D., Neefe, J. R., Rothman, J., Rudnick, S., Galicky, P., and Schein, P. S., 1984, A phase II trial of high-dose intravenous interferon alpha-2 in advanced colorectal cancer. Cancer 54:2257–2261.
Silverberg, E., 1984, Cancer statistics, Cancer J. Clin. 34:14.
Silverberg, E., and Lubera, J., 1986, Cancer statistics. Cancer J. Clin. 36:9.
Silverberg, E., and Lubera, J., 1987, Cancer statistics. Cancer J. Clin. 37:2.
Silverberg, E., and Lubera, J. A., 1988, Cancer statistics, 1988, Cancer J. Clin. 38:5–22.
Sinkovics, J. G., 1986, Colorectal carcinoma, in: Medical Oncology, an Advanced Course, Vol. 2, Marcel Dekker, New York, pp. 981–1045.
Smith, J., Bookman, M., Carrasquillo, S., Larson, S., Reynolds, J., Dailey, V., Perentesis, P., Urba, W., McKnight, J., Clark, J., McCabe, R., Hanna, M., Haspel, M., Longo, D., and Steis, R., 1987, Evaluation of a human anti-colorectal carcinoma monoclonal antibody in patients with metastatic colorectal cancer, Proc. ASCO 6:250.
Solal-Celigny, P., Simeon, J., Herrera, A., Vinci, G., Bertrand, O., Mahieu, P., Kinet, J. P., Raspaud, S., Sinegre, M., and Boivin, P., 1986, Effects of ex-vivo plasma adsorption over protein A sepharose in acute leukemia. Leuk. Res. 10:643–649.
Soloway, M. S., and Perry, A., 1987, Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C, J. Urol. 137:871–873.
Spitler, L. E. Wybran, J., Rudenberg, H. H., Pirofsky, B., August, C. S., Stiehm, R., Hitzig, W. H., Gatti, R. A., 1972, Transfer factor therapy of malignant melanoma, J. Clin. Invest. 51: 3216–3224.
Steinitz, M., Klein, G., Koskimies, S., and Makel, O., 1977, EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 269:420–422.
Sterchi, J. M., Wells, H. B., Case, L. D., Spurr, C. L., White, D. R., Richards, F., Muss, H. B., Jackson, D. V., Stuart, J. J., Cooper, R., and the Piedmont Oncology Group, 1985, A randomized trial of adjuvant chemotherapy and immunotherapy in stage I and stage II cutaneous melanoma. Cancer 55:707–712.
Suen, J. Y., Richman, S. P., Livingston, R. B., Hersh, E. M., Craig, R., and Tonymon, K., 1977, Results of BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neck. Am. J. Surg. 134:474–478.
Symonds, E. M., Perkins, A. C., Pimm, M. V., Baldwin, R. W., Hardy, J. G., and Williams, D. A., 1985, Clinical implications for immunoscintigraphy in patients with ovarian malignancy: A preliminary study using monoclonal antibody 791T/36, Br. J. Obstet. Gynaecol. 92:270–276.
Takita, M., Hollinshead, A., Hart, J. T., Bhayana, J., Adler, R., Rao, U., Moskowitz, R., and Ramundo, M., 1985, Adjuvant specific immunotherapy of resectable squamous cell lung carcinoma. Analysis at the eighth year. Cancer Immunol. Immunother. 20:231–235.
Taylor, S. G., Sisson, G. A., Bytell, D. E., Raynor, J. W. J., 1983, A randomized trial of adjuvant BCG inmiunotherapy in head and neck cancer. Arch. Otolaryngol. 109:544–548.
Taylor-Papadimitrous, J., 1984, Effects of interferons on cell growth and function, in: Interferon General and Applied Aspects (A. Billiau, ed.), Elsevier, Amsterdam, p. 139.
Terry, W. D., and Rosenberg, S. A., 1982, Immunotherapy of Human Cancer, Elsevier/North- Holland, New York.
Thatcher, N., Honeyboume, D., Wagstaff, J., Carroll, K. B., Barber, P. V., Morrison, J. B., and Crowther, D., 1984, Moderate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancer, Br. J. Dis. Chest 78:89–97.
Thatcher, N., Mene, A., Baneijee, S.S., Craig, P., Gleave, N., and Orton, C., 1986a, Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma, Br. J. Surg. 73:111–115.
Thatcher, N., Wagstaff, J., Mene, A., Smith, D., Orton, C., and Craig, P., 1986b, Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma, Eur. J. Cancer Clin. Oncol. 22:1009–1014.
Tokunaga, T., Yamamoto, S., Nakamura, R. M., and Katoaka, T., 1974, Immunotherapeutic and immunoprophylactic effects of BCG on 3-methylcholanthrene-induced autochthonous tumors in Swiss mice, J. Natl. Cancer Inst. 53:459–463.
Torti, F. M., and Lum, B. L., 1984, The biology and treatment of superficial bladder cancer, J. Clin. Oncol. 2:505–531.
Torti, F. M., and Lum, B. L., 1987, Superficial bladder cancer: Risk of recurrence and potential role for interferon therapy. Cancer 59:613–616.
Torti, F. M, Shortliffe, L. D., Williams, R. D., Spaulding, J. T., Hannigan, J. F., Jr., Palmer, J., Meyers, F. J., Higgins, M., and Freiha, F. S., 1984, Superficial bladder cancers are responsive to alpha-2 interferon administered intravesically, Proc. Am. Soc. Clin. Oncol. 3:160.
Torti, F. M., Shortliffe, L. D., Williams, R. D., Pitts, W. C., Kempson, R. L., Ross, J. C., Palmer, J., Meyers, F., Ferrari, M., Hannigan, J., Spiegel, R., McWhirter, K., and Freiha, F., 1988, Alpha-interferon in superficial bladder cancer: A Northern California Oncology Group study, J. Clin. Oncol. 6:476–483.
Treumiet-Donker, A. D., Meischke-de Jongh, M. L., van Putten, W. L. J., 1987, Levamisole as adjuvant immunotherapy in breast cancer. Cancer 59:1590–1593.
Trump, D. L., Elson, P. J., Borden, E. C., Harris, J. E., Tuttle, R. L., Whisnant, J. K. Oken, M. M., Carignan, J. R., Ruckdeschel, J. C., and Davis, T. E., 1987, High-dose lymphoblastoid interferon in advanced renal cell carcinoma: An Eastern Cooperative Oncology Group study. Cancer Treat. Rep. 71:165–169.
Tykka, H., 1981, Active specific immunotherapy with supportive measures in the treatment of advanced palliatively nephrectomised renal adenocarcinoma. A controlled clinical study, Scand. J. Urol. Nephrol. (Suppl.) 63:1.
Umeda, T., and Niijima, T., 1986, Phase II study of alpha interferon on renal cell carcinoma, Cancer 58:1231–1235.
Vadhan-Raj, S., Nathan, C. F., Sherwin, S. A., Oettgen, H. F., and Krown, S. E., 1986, Phase I trial of recombinant interferon gamma by 1-hour iv infusion. Cancer Treat. Rep. 70:609–614.
van der Burg, M., Edelstein, M., Gerlis, L., Liang, C.-M., Hirschi, M., and Dawson, A., 1985, Recombinant interferon-γ (immuneron): Results of a phase I trial in patients with cancer, J. Biol. Resp. Mod. 4:264–272.
Veltman, L. L., Kern, D. H., and Pilch, Y. H., 1974, Immune cytolysis of human tumor cells mediated by xenogenic “immune” RNA, Cell. Immunol. 13:367–377.
Vilcek, J., Kelke, H. C., Jinmiing, L. E., and Yip, Y. K., 1985, The structure and function of human interferon-a, in: Mediators in Cell Growth and Differentiation (R. J. Ford, ed.). Raven Press, New York, pp. 299–313.
Vitetta, E. S., and Uhr, J. W., 1985, Immunotoxins, Annu. Rev. Immunol. 3:197–212.
Volberding, P. A., Mitsuyasu, R. T., Golando, J. P., and Spiegel, R. J., 1987, Treatment of Kaposi’s sarcoma with interferon alpha-2b (IntronRA), Cancer 59:620–625.
Vugrin, D., Hood, L., Taylor, W., and Laszio, J., 1985, Phase II study of human lymphoblastoid interferon in patients with advanced renal carcinoma, Cancer Treat. Rep. 69:817–820.
Walker, A. E., Robins, M., and Weinfeld, F. D., 1985, Epidemiology of brain tumors: The national survey of intracranial neoplasms, Neurology 35:219–226.
Wallack, M. K., McNally, K. R., Leftheriotis, E., Sciger, H., Balch, C., Wanebo, H., Bartolucci, A. A., and Bash, J. A., 1986a, A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates, Cancer 57:649–655.
Wallack, M. K., McNally, K., Michaelides, M., Bash, J., Bartolucci, A., Siegler, H., Balch, C., and Wanebo, H., 1986b, A phase I/II SECSG (Southeastern Cancer Study Group) pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO), Am. Surgeon 52:148–151.
Weiner, R. S., Reich, S. D., Youngblood, M. W., and Witman, P. A., 1987, Phase I/II study of r- interferon-gamma and BCNU in metastatic melanoma, Proc. AACR 28:377.
Weiss, D. W., 1972, Nonspecific stimulation and modulation of the immune response and of states of resistance by the MER fraction of tubercle bacilli, Natl. Cancer. Inst. Monogr. 35:157–171.
Weiss, D. W., Bonhag, R. S., and Parks, J. A., 1964, Studies on the heterologous immunogenicity of a methanol-insoluble fraction of attenuated tubercle bacilli (BCG), J. Exp. Med. 119:53–70.
Welander, C. E., 1987, Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxic drugs. Cancer 59:617–619.
Winchester, R. J., Wang, C.-Y., Gibofsky, A., Kunkel, H. G., Lloyd, K. O., and Old, L. J., 1978, Expression of la-like antigens on cultured human malignant melanoma cell lines, Proc. Natl. Acad. Sci. U.S.A. 75:6235–6239.
Winkelhake, J. L., Stampfl, S., and Zimmerman, R. J., 1987, Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models. Cancer Res. 47:3948–3953.
Woods, J. E., DeSauto, L. W., and Ritts, R. E., 1977, A controlled study of combined methotrexate, BCG, and INH therapy for squamous cell carcinoma of the head and neck, Surg. Clin. North Am. 57:769–778.
Yang, Y.-C., Ciarletta, A. B., Temple, P. A., Chung, M. P., Kovacic, S., Witek-Giannotti, J. S., Leary, A. C., Kriz, R., Donahue, R. E., Wong, G. G., and Clark, S. C., 1986, Human IL-3 (multi-CSF): Identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3, Cell 47:3–10.
Yasumoto, K., Yaita, H., Ohta, M., Azuma, I., Nomoto, K., Inokuchi, K., and Yamamura, Y., 1985, Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative lung cancer patients, Cancer Res. 45:1413–1417.
Yasumoto, K., Miyazaki, K., Nagashima, A., Ishida, T., Kuda, T., Yano, T., Sugimachi, K., and Nomoto, K., 1987, Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res. 47:2184–2187.
Zenner, H. P., Kley, W., Claros, P., Claros, A., Labas, Z., Lobe, L. P., Pavelka, R., Plath, P., Ribari, O., Niethammer, D., and Hirche, H., 1985, Recombinant interferon-alpha-2C in laryngeal papillomatosis: Preliminary results of a prospective multicentre trial. Oncology 42 (Suppl. 1):15–18.
Ziai, M. R., Imberti, L., Tongson, A., and Ferrone, S., 1985, Differential modulation by recombinant immune interferon of the expression and shedding of HLA antigens and melanoma associated antigens by a melanoma cell line resistant to the antiproliferative activity of immune interferon. Cancer Res. 45:5877–5882.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Plenum Press, New York
About this chapter
Cite this chapter
Taylor, C.W., Hersh, E.M. (1990). Immunotherapy and Biological Therapy of Cancer. In: Hadden, J.W., Szentivanyi, A. (eds) Immunopharmacology Reviews. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-7252-7_3
Download citation
DOI: https://doi.org/10.1007/978-1-4615-7252-7_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4615-7254-1
Online ISBN: 978-1-4615-7252-7
eBook Packages: Springer Book Archive